Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN57,4557,490,35
Msft-0,51
Nokia4,764,79050,09
IBM0,81
Mercedes-Benz Group AG61,461,420,31
PFE-0,43
15.02.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 14.02.2025 21:59:32
Ultragenyx Pharm (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
42,49 -2,37 -1,03 1 008 163
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 16.02.2025
Popis společnosti
Obecné informace
Název společnostiUltragenyx Pharmaceutical Inc
TickerRARE
Kmenové akcie:Ordinary Shares
RICRARE.O
ISIN-
Prioritní akcieConv. Pref. Shrs
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2023 1 276
Akcie v oběhu k 31.10.2024 92 344 268
MěnaUSD
Kontaktní informace
Ulice60 Leveroni Ct
MěstoNOVATO
PSČ94949-5746
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 154 838 800
Fax14154838810

Business Summary: Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Ultragenyx Pharmaceutical Inc revenues increased 29% to $395.4M. Net loss decreased 10% to $435.8M. Revenues reflect Crysvita non-cash collaboration royalty revenue segment increase of 70% to $181.8M, Crysvita segment increase of 96% to $112.3M, Latin America segment increase of 90% to $112.2M, Europe segment increase of 68% to $54.4M.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 16.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorEmil Kakkis63
Chief Financial Officer, Executive Vice President, Corporate StrategyHoward Horn4612.10.202309.10.2023
Executive Vice President, Chief Technical Operations Officer and Gene Therapy OperationsDennis Huang5904.06.2015
Executive Vice President, Chief Legal Officer, General CounselKarah Parschauer4620.06.2016
Executive Vice President, Chief Medical OfficerEric Crombez5101.05.202301.05.2023
Executive Vice President, Chief Commercial OfficerErik Harris5417.06.201917.06.2019
Chief Business Officer, Executive Vice PresidentThomas Kassberg63
Chief Quality Officer, Executive Vice President - Translational SciencesJohn Pinion5813.07.2015